sign recoveri normal stack
result impact trough
mdt result april end declin organ ep in-
line press releas april consist impact covid across
industri gm neg impact driven larg increas expens
due covid neg mix believ seen worst procedur
declin see encourag sign recoveri around world howev given
full quarter covid impact expect revenu growth modestli
wors total compani group continu rate
share buy think new product introduct carri higher
normal growth rate futur year help push multipl mdt
balanc sheet also give stabil weather storm may enabl add
growth futur
recoveri year
provid formal guidanc despit see encourag sign
mani geographi expect better q/q improv
though year expect normal revenu growth stack
basi normal margin time well get call larg
health system ask readi faster-than-expect recoveri
strong balanc sheet time
strong balanc sheet need rais capit unlik
peer done rais recent ceo geoff martha note good time
 asset price say partial tuck-in
meaning affect long-term growth rate
valuat lower estim pt reflect covid disrupt
trade con ep april end compar peer like
fy new pt base
ep prior pt base ep
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price may edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
recoveri track geograph busi perform
believ seen worst procedur declin see
encourag sign recoveri around world howev given addit week
covid impact expect revenu growth modestli wors
total compani group expect rtg
challeng near term follow cvg expect declin
total compani mitg diabet better compani
averag still declin think bit conserv appear
impli much improv may math also addit
sell week someth happen everi year given
april contribut minim amount revenu
quarter
quarter
work
extra week
earlier expect
qoq
segment due
usa eu
earli may
declin compani averag
declin compani averag
better compani averag
better compani averag
expect better q/q improv though year
expect normal revenu growth stack basi
normal margin time well get call larg health
system ask readi faster-than-expect recoveri
hospit run higher normal level think
major think patient defer procedur
first wave taken care pent-up demand big
consider predict normal growth stack
china lead indic revenu declin quarter
feb march gradual sequenti improv midway
march april may improv high-
teen declin apac sale declin korea anz
japan japan india given lockdown y/i declin
could sever anz korea continu see recoveri
emea sale declin western europ track expect
mid-march declin april may weekli revenu across
america sale declin us track
expect mid-march see signific declin us
declin earli may
categori pipelin first recent approv product second
review product third product trial recent approv
product covid interrupt launch europ includ
percept pc db interstim micro recharg sacral nerv stimul cobalt
chrome high power diamond temp ablat cathet
us covid slow launch av fistula indic pact admir
dcb dtp therapi pain micra av pacer feb march grew
us also receiv approv micra av reveal linq
europ cobolt chrome product particularli help covid given
bluetooth enabl high power devic us distanc
program better remot monitor
micra av reveal linq europ
dtm therapi pain
upgrad target launch summer
minim us target launch end
product regulatori review impact much
us expect approv interstim micro sacral nerv stimul
percept pc db reveal linq europ expect approv minim
us expect approv summer bluetooth
enabl allow wireless air softwar upgrad launch
later fiscal year first hybrid close loop system
patient age rang custom purchas get free
soft tissu robot delay final system
preclin test timelin provid
submiss end summer synergi sensor
submiss within next week
softwar upgrad approv expect show pivot result
hybrid close loop algo adult june ada confer
enrol clinic trial slow includ soft tissu robot product
diabet cgm sensor robot mdt abil final system
preclin test delay although tri expedit work
remain optimist cgm intend submit data end
summer synergi sensor submiss next week
renal denerv combin on-m data recent present
off-m data support us approv
cite four factor drove differ individu busi result
mix urgent procedur vs one deferr urgent
procedur feel lesser impact loss larg bulk purchas near end
quarter tend larger april fy end continu
acceler effort reduc bulk hospit surgeri center delay
capit purchas small busi product servic
saw increas demand due
cite covid case volum potenti resurg play role
updat recommend govern agenc resumpt
elect procedur provis non-covid relat healthcar hospit
capac anoth factor new protocol design ensur patient provid
safeti slot return full capac system plan
increas capac extend workday ad procedur weekend
case region hospit also maintain surg capac
case second wave assum potenti second wave
adequ contain prepar rang scenario
result declin due procedur delay lockdown
cvg group declin although less deferr
substanti declin volum reduct bulk purchas around dx
tavr
mitg sale declin revenu mix middl defer
spectrum signific declin surgic innov gi
declin low rang off-set growth respiratori
patient monitor renal care solut respiratori patient monitor
grew mid-teen signific growth airway vent significantli
ramp product vent strong demand puls ox product off-set
hospit procedur renal care grew hsd driven access cathet
acut chronic dialysi product dialysi treatment continu
pandem
patient monitor given
rtg sale declin therapi tend use procedur
deferr includ spine pain stim ent pelvic health
also impact reduct bulk capit equip purchas
neuro high capit mix
diabet declin delay new patient start insulin pump
result close physician offic off-set increas demand diabet
suppli includ infus set particularli intern market
gm due cost manufactur bonus higher
freight clean etc also neg impact mix yoy
increas china tariff opex impact continu spend
sg protect variabl comp rep
expect gm pressur due lower volum mix cost
manufactur plant oper less full capac could
point qoq take short-term view believ
come stronger invest product employe
mix lower volum extra safeti cost
valuat method risk statement
price target base ep risk
price target includ slowdown core cardio neuro spine surgic end
market increas competit establish larg cap compani
competit entrant differenti technolog delay key product
approv reject regulatori bodi inabl deliv top-lin growth
meet consensu expect top line miss guidanc consensu
bottom line delay robot launch timelin mitral project
meet expect chang regulatori environ lead longer
lead time higher bar approv
report prepar ub secur llc affili ub ag ub ag subsidiari branch affili
refer herein ub
inform way ub manag conflict maintain independ research product histor
perform inform certain addit disclosur concern ub research recommend term
condit certain third parti data use research report pleas visit www ub com/disclosur figur contain
perform chart refer past past perform reliabl indic futur result addit inform
made avail upon request ub secur co limit licens conduct secur invest consult
busi china secur regulatori commiss ub act may act princip debt secur
relat deriv may subject report recommend final may pm
gmt ub design certain research depart member deriv research analyst depart
member publish research princip analysi price market deriv provid inform
reason suffici upon base decis enter deriv transact deriv research
analyst co-author research report equiti research analyst economist deriv research analyst
respons deriv invest view forecast and/or recommend
analyst certif research analyst primarili respons content research report whole part
certifi respect secur issuer analyst cover report view express
accur reflect person view secur issuer prepar independ manner
includ respect ub part compens directli indirectli relat
specif recommend view express research analyst research report
fsr mra
fsr mra
fsr mra
stock price expect rise within three month time
rate assign specif catalyst event
stock price expect fall within three month time
rate assign specif catalyst event
ub rate alloc march
compani coverag global within rate categori
compani within rate categori invest bank ib servic provid
within past month
compani coverag global within short-term rate categori
compani within short-term rate categori invest bank ib servic provid
within past month
definit forecast stock return fsr defin expect percentag price appreci plu gross dividend
yield next month case yield may base accru dividend market return assumpt
mra defin one-year local market interest rate plu proxi forecast equiti risk
premium review ur stock may flag ur analyst indic stock price target and/or
rate subject possibl chang near term usual respons event may affect invest case
valuat short-term rate reflect expect near-term three month perform stock
reflect chang fundament view invest case equiti price target invest horizon
except special case uk european invest fund rate definit buy posit
factor structur manag perform record discount neutral neutral factor structur
manag perform record discount sell neg factor structur manag perform record
discount band except cbe except standard band may grant invest
review committe irc factor consid irc includ stock volatil credit spread respect
compani debt result stock deem high low risk may subject higher lower band
relat rate except appli identifi compani disclosur tabl relev
